Clinical Trials Logo

Hepatitis clinical trials

View clinical trials related to Hepatitis.

Filter by:

NCT ID: NCT00132210 Completed - HIV Infections Clinical Trials

Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients

Start date: September 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether pegylated interferon therapy is effective to treat acute hepatitis C infection in HIV-coinfected individuals.

NCT ID: NCT00131742 Completed - Chronic Hepatitis B Clinical Trials

Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B

Start date: July 2004
Phase: Phase 3
Study type: Interventional

This study is being conducted to compare the effectiveness and safety of telbivudine (LdT) and lamivudine in Chinese adults.

NCT ID: NCT00128544 Completed - Hepatitis B Clinical Trials

Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B

Start date: May 2005
Phase: Phase 2
Study type: Interventional

This study is being conducted to compare the effectiveness of the combination of valtorcitabine and telbivudine to telbivudine alone in patients with chronic hepatitis B.

NCT ID: NCT00128271 Completed - Hepatitis C Clinical Trials

Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection

Start date: August 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of bavituximab when administered via a vein as a single infusion and to examine how bavituximab behaves in the body and how it affects the amount of hepatitis C virus in individuals with chronic infection.

NCT ID: NCT00127959 Completed - HIV Infections Clinical Trials

Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection

Start date: March 2004
Phase: Phase 4
Study type: Interventional

This is a randomized multicentre trial of emtricitabine (FTC) versus tenofovir (TDF)/FTC in antiretroviral naive subjects with HIV/HBV co-infection over 48 weeks (Clinical Trial A). Plus, a 12 week viral kinetic substudy comparing a subgroup of patients on Clinical Trial A is being conducted. (Substudy A1)

NCT ID: NCT00125762 Completed - Hepatitis C Clinical Trials

FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy

Start date: March 2005
Phase: N/A
Study type: Interventional

This study will examine the effectiveness of the FibroScan device in differentiating fibrosis in patients with hepatitis B and C. The FibroScan measures liver stiffness and will be correlated to the liver biopsy to see if it can diagnose the stage of liver disease. Patients who are scheduled to have a liver biopsy will also have a fibroscan and the stiffness will be correlated with the biopsy stage.

NCT ID: NCT00124241 Completed - Hepatitis B Clinical Trials

An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B

Start date: n/a
Phase: Phase 2
Study type: Interventional

This is an extension study for patients who have previously completed Idenix Study NV-02B-003. This study is being conducted to compare the safety and effectiveness of treatment beyond 1 year of telbivudine and telbivudine combined with lamivudine, a drug currently approved for the treatment of hepatitis B.

NCT ID: NCT00124215 Completed - Hepatitis C Clinical Trials

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

Start date: June 2005
Phase: Phase 1
Study type: Interventional

The GI-5005 therapeutic vaccine or placebo will be injected under the skin of hepatitis C virus (HCV) subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections.

NCT ID: NCT00122616 Completed - HIV Infections Clinical Trials

Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C

Start date: November 2003
Phase: Phase 3
Study type: Interventional

The aim of this study is to prove the efficacy of peginterferon in HIV infected patients with liver disease caused by hepatitis C virus (HCV) when the treatment to eradicate the virus failed. This scientific proof needs a comparative study to be done including two groups of patients randomly allocated: one with the treatment (peginterferon) and the other without any treatment against HCV with a duration of 2 years. To conclude, two liver biopsies are needed; one before the study and a second 2 years after.

NCT ID: NCT00120861 Completed - Chronic Hepatitis C Clinical Trials

Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy

Start date: January 2005
Phase: Phase 2
Study type: Interventional

This study is being conducted to compare the safety, effectiveness and tolerance of valopicitabine (NM283) when used alone and when valopicitabine is used together with pegylated interferon in hepatitis C treatment failure patients. These results will be compared against the results of treatment with pegylated interferon plus ribavirin, the current standard therapy for treatment of hepatitis C viral infection.